Latest available: Nov 13, 2026 · updates irregularly
Each axis is a 0 to 100 percentile rank among equities
Not scored: Equity peers
What each one means
LiquidityNot scored
Higher scores reflect greater average dollar trading volume and less absolute return per dollar traded over 21 sessions within equity peers.
ShortNot scored
Higher scores reflect less short-interest pressure relative to trading volume and the company's own history, and less growth in shares short, within equity peers.
SqueezeNot scored
Higher scores reflect a higher published Squeeze score within equity peers.
TrendNot scored
Higher scores reflect a price nearer its 252-session split-adjusted closing high and positive 63- and 126-session total returns.
MomentumNot scored
Higher scores reflect stronger 63- and 126-session total returns within equity peers.
ValuationNot scored
Higher scores reflect lower positive P/E, P/B, EV/EBITDA and price/sales multiples within equity peers; limited data pulls the score toward neutral.
StabilityNot scored
Higher scores reflect lower daily total-return volatility over 63 and 252 sessions within equity peers.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.